Biosimilars

FDA Approves Ruxience, a Rituxan Biosimilar

July 23, 2019

CD20-directed antibody indicated for several cancers and other conditions.

FDA Finalizes Guidance on Interchangeability for Biologics

May 10, 2019

Biosimilar guidance provides “clarity” for drug developers.

Trazimera, Herceptin Biosimilar, Gains FDA Approval

March 12, 2019

Indicated for breast cancer, and gastric or gastroesophageal junction adenocarcinoma. 

Biosimilar Naming Change Eliminates Potentially High Consumer Costs

March 08, 2019

Only new biosimilars and interchangeables will recieve four-letter suffixes.

Better Management Strategies Needed, Suggests Ninth Annual Medical Pharmacy Trend

February 19, 2019

The report by Magellan Rx Management indicates PMPM, site of service, and Medicaid prices continue to increase. 

Specialty Pharma to be Half of Total Drug Spend in a Few Years

December 13, 2018

Specialty pharmaceuticals make up a significant part of the current drug market, and their impact is only going to grow over the next few years.

The Push Is on for Generics and Biosimilars

September 03, 2018

Stalled competition hurts consumers and may keep prices higher.

What the FDA Wants Pharmacists to Know About Generic Drugs

August 24, 2018

Drug Topics recently spoke with the FDA about the role pharmacists can play in patient education.

A Look at the Year in Generics

August 23, 2018

The annual report on generic access and savings shows some impressive numbers for 2017.

FDA-Mandated Biosimilar Names Are Confusing

August 16, 2018

An unclear naming system for biosimilars could affect patient safety.

x